The proportion of commercially sponsored clinical trials run in Europe almost halved over the last 10 years and is now trailing China, whose share has doubled in the same period.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.